Charged Alpha Stock Encyclopedia

Bloom Energy Corporation (BE) Q2 2026 — Bloom Energy (BE) reported Q2 2026 (quarter ended June 30) on July 28. Revenue was $1.0654B, up 165.5% y/y and the first billion-dollar quarter in company history; product revenue was $935.4M (+215.4%). GAAP operating income was $182.2M vs a $3.5M loss last year, GAAP diluted EPS $0.62, and non-GAAP EPS $0.78 against a ~$0.41 consensus. Gross margin rose 668 bps to 33.4%. Operating cash flow was +$226.4M vs -$213.1M a year ago, a $439.5M swing. FY2026 guidance was raised to $3.9-4.2B revenue and $2.55-$2.85 non-GAAP EPS. The stock fell 11.3% to $166.84 on the print, then rallied to $207.12. Why we're cautious: enterprise value is ~$67B against ~$495M of FY26E free cash flow, a 0.7% yield, and our probability-weighted fair value is ~$95. Our call: AVOID, 4/5.

A split decision, and we want both halves on the record. On the business we side with the company and against the short sellers. Hunterbrook's July 8 report claimed Bloom advertises a '$20 billion contracted backlog' while its audited filings show only ~$492M of remaining performance obligations. We pulled the 10-Q: as of June 30 unsatisfied performance obligations were $442.4M (product and installation) plus $51.7M (service) — $494.1M. The number is right; the inference is wrong by construction. The very next sentence discloses that Bloom excludes contracts with an original expected length of one year or less and contracts billed as work is performed — exclusions that remove nearly the entire business. The cash tiebreaker is decisive: deferred revenue and customer deposits went from $143.8M at year-end to $445.0M; net of $84.5M of true deferred revenue, that is roughly $360M of customer deposits, up from ~$78M. And the 'H2 math test' was passed outright — the LOW end of the raised guide implies second-half quarters averaging 2.2% BELOW the quarter just reported. The catch is the price, and the risk nobody was short: the 10-Q concentration note shows two counterparties at 44% and 21% of Q2 revenue, and approximately 73% of first-half revenue running through a single contractual counterparty (which Bloom's own footnote says may be a project-finance affiliate rather than the end user). Add $428.3M of contract assets (revenue booked, not yet billed), a diluted share count up 39% y/y, and a $2.67B cash pile offset by $2.68B of debt for ~$4M of net cash. At ~$67B EV the price requires roughly 35% free-cash-flow growth for ten consecutive years.

THE CALL: AVOID (4/5, THE BACKLOG ATTACK FAILED — AND THE PRICE STILL ASSUMES A FLAWLESS DECADE) — base-case value ~$95.00 vs ~$207.12 today.

What to watch: Top-customer concentration falling below 40% (from ~73% of H1 revenue through one counterparty); second-half revenue above $2.4B, beating the top of the raised guide; and FY2027 free cash flow above $800M with capex normalising. The risks: a single counterparty slipping — Oracle's Project Jupiter still has no approved natural-gas pipeline after a second New Mexico rejection in July — and contract assets ($428.3M of unbilled revenue) continuing to outgrow collections.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Vertiv Holdings Co (VRT) Q2 2026 — Vertiv (VRT) reported Q2 2026 (quarter ended June 30) on July 29. Adjusted diluted EPS was $1.52 (+60% y/y) against a ~$1.43 consensus — a clear beat. Adjusted operating profit rose 51% to $738M, adjusted operating margin expanded 410 bps to 22.6%, operating cash flow rose 241% to $1,100M and adjusted free cash flow rose 234% to $925M. Net sales of $3,274M grew 24% (18% organic, 5% M&A, 1% FX) but landed ~$107M below the ~$3,381M consensus and ~$76M below Vertiv's own guidance midpoint. Management raised FY2026 across the board: revenue to $14,000M midpoint (+$250M), adjusted operating profit to $3,325M (+$125M), adjusted EPS to $6.70 (+$0.35) and adjusted free cash flow to $2,500M (+$300M). The stock still fell 17.3% on the print, from $269.56 to $223.04, and trades near $229 today. Our DCF lands at ~$205. Our call: HOLD, 3/5.

A quarter where profit, margin, cash flow and guidance all went up — and the stock lost roughly $17.9 billion of market value in one session over a $107 million revenue shortfall. That is 167 dollars of market cap destroyed per dollar missed, which tells you the market was not pricing the quarter; it was repricing the trajectory. Vertiv blamed the miss on 'temporary supply chain congestion and multi-phased project execution' — timing, not demand. That claim is testable: backlog, book-to-bill and organic orders growth would settle it in one line. We read all three primary documents (the 8-K earnings release, the results presentation, and the 10-Q) and none of them disclose backlog, book-to-bill or orders growth. Two quarters earlier Vertiv led its release with a $15.0B backlog, a ~2.9x book-to-bill and 252% organic orders growth. Those metrics went dark in exactly the quarter they were needed. What Vertiv cannot hide is the audited balance sheet — and it supports management: deferred revenue (customer cash paid for undelivered equipment) went from $1,814.7M in December to $3,633.7M in June, with $1,171.5M added in Q2 alone; inventories rose ~$1,066M; capex tripled to $173M and is going to the high end at ~4% of sales. Nobody raises four guidance numbers into decelerating demand. But being right about the quarter does not make the stock cheap: the FY guide now implies a Q4 of roughly $4,326M, up about 50% year over year — the largest quarter in company history, an acceleration, from the same operations that just slipped. EMEA is down 14.8% organically in the first half. At ~34x FY26 adjusted EPS and a 2.8% free-cash-flow yield, our DCF says ~$205 vs $229 today.

THE CALL: HOLD (3/5, THE MARKET WAS RIGHT TO SELL AND WRONG ABOUT WHY — A GREAT BUSINESS WITH NO MARGIN OF SAFETY) — base-case value ~$205.00 vs ~$229.05 today.

What to watch: Q3 revenue landing inside the $3,650M-$3,850M guide (the single cleanest test of the timing explanation); EMEA actually returning to organic growth in H2 after -2.4% in Q2 and -14.8% in H1; deferred revenue continuing to climb, since customer prepayments are the pillar the whole timing argument rests on; and Vertiv putting backlog and book-to-bill back into the earnings release, which costs management nothing and would restore the most credibility. The risks: a second consecutive revenue slip, any trim to the implied ~50%-growth Q4, EMEA staying negative, and a multiple that still assumes an uninterrupted AI capex cycle.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Ecolab Inc. (ECL) Q2 2026 — Ecolab (ECL) reported Q2 2026 (quarter ended June 30) on July 28. Reported sales were $4.4154B (+10%), organic sales accelerated to +5%, GAAP diluted EPS was $1.90 (+3%) and adjusted diluted EPS was $2.09 (+11%) against a ~$2.08 consensus — a one-cent beat. Organic operating income margin improved 40 bps to 18.8%, and FY2026 adjusted EPS guidance was raised from $8.03-$8.23 to $8.05-$8.25: a two-cent raise. The stock rose ~4.2% to $282.90 on the print and eased to ~$277.11. Why we're cautious: at ~34x forward earnings the free-cash-flow yield is ~2.4%, and pro-forma net debt jumped to ~$12.8B after the $4.75B CoolIT deal. Our DCF lands at ~$235. Our call: HOLD, 3/5.

A very ordinary quarter attached to a genuinely big story. The good: pricing improved to 4% as Ecolab pushed a global energy surcharge through in a single quarter, organic operating income margin rose 40 bps to 18.8%, and H2 pricing is guided to 5-6%. Global High-Tech grew 29% organically, Life Sciences grew 15% with operating income +46% and margin up from 21.0% to 26.5%, and Ecolab Digital rose 27% to $121M. On July 2 Ecolab closed the $4.75B CoolIT acquisition early, taking Global High-Tech to ~$1.5B annualized with a stated $4B-by-2030 target at 25% margins. The catch: volume grew only 1% (with a ~1 pt Middle East drag), so almost all growth was price. Global Water — half the company — grew organic operating income just 1% with margin down to 15.7%. Reported operating margin actually FELL 40 bps to 17.2%; adjusted was flat at 18.3%; only the organic measure expanded. FY26 special charges are guided at $0.75-$0.80/share, about a tenth of adjusted EPS. And free cash flow of ~$1.87B on a ~$78B market cap is a 2.4% yield.

THE CALL: HOLD (3/5, AN OUTSTANDING BUSINESS AT A PRICE THAT ALREADY ASSUMES A PERFECT DECADE) — base-case value ~$235.00 vs ~$277.11 today.

What to watch: Q3 volume staying positive while pricing runs 5-6% (price without volume is the whole risk); organic operating margin actually printing the guided ~20% in H2; FY2027 free cash flow above $2.3B; and a CoolIT revenue disclosure showing the $4B-by-2030 path is tracking. The risks: a commodity re-spike after the one-time surcharge lever is spent, CoolIT's doubling proving to be a one-year AI order surge, and leverage staying near 3.1x.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

GE HealthCare Technologies (GEHC) Q2 2026 — GE HealthCare (GEHC) — the medical imaging company spun out of General Electric in January 2023 — reported Q2 2026 (quarter ended June 30) on July 29. Revenue was $5.295B (+5.7%, +3.5% organic), GAAP diluted EPS $1.24 vs $1.06, and adjusted EPS $1.13 vs the ~$1.04 consensus. Organic orders grew a record 11.1%, book-to-bill hit 1.15x and backlog reached a record $23.9B. The stock jumped ~12% to $71.90, then gave part of it back to ~$69.12. Why we're cautious: adjusted EBIT margin FELL 40 bps to 14.2%, adjusted EBIT grew only 2.9% on 5.7% revenue growth, and the beat was helped by IEEPA tariff refunds and a ~17% tax rate. Our free-cash-flow DCF lands at ~$57 vs $69.12. Our call: HOLD, 3/5.

A genuinely strong demand quarter attached to a genuinely weak profit quarter. The good: record organic orders +11.1% (vs 3.4% a year ago) across every segment, 1.15x book-to-bill, record $23.9B backlog — orders lead revenue by a year or more in imaging. Pharmaceutical Diagnostics grew 15.6% to $843M at a 29.6% EBIT margin; Advanced Imaging Solutions grew 7.9% to $3.771B with margin up 90 bps to 13.9%. But three things sit underneath. First, operating leverage went the wrong way: revenue +5.7% but adjusted EBIT only +2.9% to $750M, margin DOWN 40 bps to 14.2%, hurt by ~$250M of full-year inflation from memory chips, oil and freight. Second, the quality of the beat: $129M of IEEPA tariff refunds ($106M from 2025 excluded from adjusted EBIT, $23M from 2026 included) and a ~17.2% GAAP tax rate against 20-21% guidance — the release itself credits 'tariff refunds as well as a lower tax rate.' Third, Patient Care Solutions collapsed: revenue -13.3% to $675M, segment EBIT NEGATIVE $26M, a -3.8% margin down 1,150 bps, and management is now 'reviewing strategic options' for it. Also: Imaging and Advanced Visualization merged into one segment (GEHC now reports three); CFO Jay Saccaro departs August 14 with George Newcomb interim; China is guided to DECLINE on volume-based procurement. FY2026 guidance was REAFFIRMED, not raised: 3-4% organic growth, 15.4-15.7% adjusted EBIT margin, $4.80-5.00 adjusted EPS, ~$1.6B free cash flow. That guide is the debate. First-half adjusted EBIT margin was 13.8%, so the back half must run above 17%. First-half free cash flow was $180M ($458M operating cash flow less $278M capex), so the back half must produce ~$1.42B — about 89% of the year in two quarters — and Q2's $168M of operating cash flow included a $107M tariff refund. We value the cash: ~$4.05B of FY26 adjusted EBITDA converts to only ~$1.6B of free cash flow after ~$550M cash interest, ~$500M cash taxes, ~$820M working capital and other, and ~$580M capex. Grow $1.5B of normalized free cash flow 8% for five years then 5%, discount at 9%, subtract ~$8.0B net debt, divide by ~455M shares: ~$57, about 21% below the price. A reverse DCF says $69.12 needs ~5.0% free-cash-flow growth forever against 3-4% guided organic growth.

THE CALL: HOLD (3/5, RECORD ORDERS AND A RECORD BACKLOG — BUT THE MARGIN WENT BACKWARDS AND THE CASH ISN'T THERE YET) — base-case value ~$57.00 vs ~$69.12 today.

What to watch: Q3 adjusted EBIT margin printing above 16%, which would show the back-half ramp is real; Q3 free cash flow of $700M or more; and an announced sale or exit of Patient Care Solutions, which would add roughly a point of consolidated margin. The risks: a full-year guidance cut, which becomes likely if Q3 shows no margin expansion; memory-chip and freight inflation running past the ~$250M assumption; China deteriorating faster than the guided decline; and a permanent CFO hired externally who rebases the numbers.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Amneal Pharmaceuticals (AMRX) Q2 2026 — Amneal Pharmaceuticals (AMRX) — the Patel brothers' complex-generics and branded-neurology drugmaker — reported Q2 2026 (quarter ended June 30) before the open on July 30. Net revenue was $796.2M (+10%), adjusted EPS $0.30 (+20%), adjusted EBITDA $206.5M (+12%), and management RAISED full-year guidance for the second time this year. The stock still fell about 5% to $18.21 after closing at a record $19.10. Why: first-half operating cash flow was NEGATIVE $47.99M versus POSITIVE $91.2M a year ago, net debt rose $244M to $2.66B, and net leverage ticked UP to 3.6x. Our free-cash-flow-to-equity DCF lands at ~$15 vs $18.21. Our call: HOLD, 3/5.

This was a good quarter by almost every reported measure — and the market sold it anyway. Amneal grew revenue 10% to $796.2M, expanded gross margin from 39.5% to 42.0%, grew adjusted EBITDA 12% to $206.5M, and raised FY2026 guidance to $3.10-3.20B revenue, $750-780M adjusted EBITDA and $0.96-1.06 adjusted EPS. Specialty revenue rose 17% to $149.3M on CREXONT, BREKIYA and UNITHROID at an 80.3% adjusted gross margin; Affordable Medicines rose 13% to $489.9M. But three things sit underneath the headline. First, the celebrated 157% GAAP earnings jump to $0.18 is largely a tax artifact: the provision was $1.376M, an effective rate under 2%, against 31% a year ago — pre-tax income rose 37% while net income rose 96%. Second, the cash. Six-month operating cash flow was negative $47.99M against positive $91.2M last year as receivables built $125.8M and inventories built $124.2M; cash fell from $282.0M to $127.6M, net debt rose to $2.657B and net leverage rose to 3.6x from 3.5x even as EBITDA grew. The full-year guide of $350-400M operating cash flow now requires roughly $400-450M in the back half. Third, the raise was small — revenue up $50M at the midpoint (1.6%), adjusted EBITDA up $10M, adjusted EPS up a single penny — after a quarter that beat by 10% on revenue. Credit where due: the July repricing of the $2.084B Term Loan B from SOFR+300 to SOFR+250 saves ~$12M a year, and interest expense already fell from $65.1M to $55.0M. But another $350M term loan is coming to fund the Kashiv BioSciences acquisition, and the sub-3.0x leverage target is not until 2028. Bridging guided adjusted EBITDA of ~$765M down through cash interest, capex, cash taxes, minority distributions and working capital leaves roughly $240M of free cash flow to equity — a ~4% yield. Our DCF lands at $10.90 (guidance path, 10%) to $16.50 (Specialty + biosimilars path, 9%); ~10x FY26 EBITDA less net debt gives ~$15. We call fair value $15.00 versus the $18.21 price — about 18% below.

THE CALL: HOLD (3/5, A REAL TURNAROUND THAT HAS ALREADY RE-RATED 133% — AND THE CASH STILL HASN'T SHOWN UP) — base-case value ~$15.00 vs ~$18.21 today.

What to watch: second-half operating cash flow actually landing inside the $350-400M guide, net leverage printing below 3.5x and falling, and Specialty crossing 20% of total revenue. The risks: working capital that never unwinds so the cash-flow guide gets cut, the Kashiv acquisition pushing gross debt past $3.1B without the EBITDA to match, or a generic price-deflation quarter — at 3.6x levered, a stumble hits the equity far harder than the business

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Takeda Pharmaceutical Company Limited (TAK) Q1 FY2026 — Q1 FY2026 (three months ended June 30, 2026) revenue was JPY 1,219.9B, +10.2% at actual exchange rates but MINUS 0.5% at constant exchange rates. Core operating profit JPY 358.9B, +11.5% AER / -0.5% CER, at a 29.4% margin. Reported operating profit JPY 201.4B (+9.1%). Reported EPS JPY 71.65, DOWN 9.8% Y/Y. Core EPS JPY 154 (+1.5% AER, -11.8% CER). Adjusted free cash flow JPY 68.6B, down 63.9% from JPY 190.1B. FY2026 guidance reaffirmed in full: revenue JPY 4,640.0B, reported operating profit JPY 420.0B, core operating profit JPY 1,160.0B (guided DOWN 5-8% at CER), reported EPS JPY 104, core EPS JPY 472 (guided down mid-teens % at CER), adjusted FCF JPY 650-750B, dividend JPY 204/share. ADR NOTE: 1 Takeda ADS = 0.5 ordinary shares, so every yen-per-share figure HALVES per ADS; converted here at spot USD/JPY 159.46 on July 30, 2026. Do not use vendor per-share data for this ADR.

Takeda reaffirmed everything and the ADR still fell ~3% — on a day the yen STRENGTHENED 2.4%, which is a tailwind for an ADR. Three things get missed. First, the entire +10.2% revenue growth is currency: at constant exchange rates revenue was -0.5% and core EPS -11.8%. Takeda's own sensitivity table (appendix A-15) says a 1% weaker yen adds JPY 20.6B of revenue but only JPY 0.42B of reported operating profit — and SUBTRACTS JPY 0.34B of net profit. That is why revenue rose 10% while reported EPS fell 9.8%. Second, the 'cheap' 11.6x core-earnings multiple excludes JPY 740B a year of charges Takeda forecasts itself: reported operating profit JPY 420.0B + JPY 413.5B product-intangible amortisation + JPY 100.0B budgeted impairments + JPY 226.5B other = JPY 1,160.0B core. That is 64% of core operating profit, and on reported earnings the ADR is at 52.8x. Third, the reaffirmed guide implies a violent second half: Q1's JPY 71.65 reported EPS is 69% of the JPY 104 full-year forecast, and the remaining three quarters imply just ~JPY 72.9B of reported operating profit each, a 64% step down from Q1. Also: adjusted net debt/adjusted EBITDA went UP from 2.6x to 2.7x against a 2.0x target, cash fell JPY 595.1B to JPY 461.0B, and Q1's JPY 150.1B dividend payment was ~6x that quarter's JPY 24.4B of pure free cash flow (though the dividend is covered ~2x across the full year). Our owner-earnings DCF with an explicit LOE-cliff assumption gives $7/ADS if the cliff bites and $23/ADS if the three launches deliver; at 55/45 that blends to about $16 versus $17.21 today. Our call: FAIRLY VALUED, 3/5, versus a Street Buy near $19-21.

THE CALL: FAIRLY VALUED (3/5, NO MARGIN OF SAFETY AT $17 — THE PRICE ALREADY IMPLIES A 64% CHANCE THE THREE LAUNCHES REPLACE THE PATENT CLIFF) — base-case value ~$16.00 vs ~$17.21 today.

What to watch: turns us bullish: two of the three launches (oveporexton/ORZEYFUL, rusfertide, zasocitinib) reaching real commercial scale with disclosed revenue, plus adjusted net debt/adjusted EBITDA back under 2.5x and adjusted free cash flow tracking to the JPY 650-750B guide rather than back-loading it. Breaks if USD/JPY heads back toward 170 (that alone cuts our fair value to about $14.70 on translation), if oveporexton slips in the US or Japan, if zasocitinib launches slowly into a heavily rebated psoriasis market, or if leverage pushes through 2.8x. Watch the December 11, 2026 Capital Markets Day.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Silicon Motion Technology Corporation (SIMO) Q2 2026 — Q2 2026 (quarter ended June 30, 2026) net sales were a record $451.001M, +32% sequentially and +127% YoY. Non-GAAP EPS was $2.43 per diluted ADS, beating the ~$2.13–2.18 consensus; GAAP EPS was $3.99 on $136.112M of net income. Gross margin expanded to 50.2% from 47.1%, and GAAP operating margin doubled to 22.4% from 11.2% ($101.114M vs $22.329M). Q3 is guided to $519–541M (+15–20% Q/Q) at a 27.5–28.5% non-GAAP operating margin, with FY revenue set to be the highest ever, +100%+. But operating cash flow was NEGATIVE $63.780M in the quarter and NEGATIVE $95.005M for the half, inventory hit $673.042M (from $208.005M), cash fell to $74.367M, and SIMO took its first bank loan, $59.183M. Note: 1 ADS = 4 ordinary shares, so all per-share figures are per ADS.

SIMO jumped ~21% on a record quarter, and on the operating lines it genuinely was exceptional. Three things get missed. First, the headline $3.99 GAAP EPS is mostly not controller profit: $74.727M of the $136.112M of net income — 55% — was realized/unrealized GAINS ON INVESTMENTS, a securities mark-up, while long-term investments went $19.620M to $127.403M and the tax rate jumped from 11.6% to 23.0%. Second, the record quarter CONSUMED cash: operating cash flow negative $63.780M (negative $95.005M for the half, ~negative $121M free cash flow), inventory up 224% to $673.042M — about 272 days of cost of sales — and a first-ever $59.183M bank loan drawn in the same quarter it paid a $16.922M dividend. Third, the model changed: the fastest-growing line, Ferri and Boot Drives (+1,690% YoY), sells FINISHED drives, so SIMO now BUYS NAND — a price spike is partly a cost, which the release concedes, and TrendForce sees 3Q26 NAND prices decelerating to +10–15% Q/Q. Also: the stock peaked at $336.90 on June 22 and fell 38% to $209.68 before the print, so this is a partial recovery, still ~25% below the high. Our mid-cycle owner-earnings DCF at 10.5% gives $125 cyclical / $197 secular, blending to $165 vs ~$253 — about 35% downside. Our call: OVERVALUED, 2/5, versus a Street Buy at $293.75.

THE CALL: OVERVALUED (2/5, A REAL BOOM AT A PEAK-CYCLE PRICE — 19x AN ANNUALIZED PEAK, ON NEGATIVE FREE CASH FLOW) — base-case value ~$165.00 vs ~$253.16 today.

What to watch: one number turns us bullish: POSITIVE operating cash flow while revenue is still growing — that would prove the $673M inventory build was a profitable bet on rising NAND, not a treadmill. Also want named MonTitan enterprise design wins and inventory days back under 200 from ~272. It breaks if inventory climbs again, NAND prices roll over, SIMO borrows more, or a top-five customer (66% of 2025 revenue) wobbles.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Allegro MicroSystems, Inc. (ALGM) Q1 FY2027 — Q1 FY2027 (quarter ended June 26, 2026) net sales were $259.243M, +27% YoY and above the top of management's own $245–255M guide — the sixth consecutive quarter of sequential growth. Non-GAAP diluted EPS of $0.23 beat the ~$0.21 consensus and rose more than 2.5x from $0.09; GAAP diluted EPS was $0.08 versus a $(0.07) loss a year ago. GAAP gross margin expanded to 48.5% from 44.9%, and GAAP operating margin swung from (1.3)% to +9.8%, with operating income of $25.467M against a $(2.740)M loss. Automotive was $165.349M (+15% YoY but only +0.9% sequentially from $163.909M); Industrial and Other was $93.894M (+59% YoY). Data center reached a record 17% of total sales (~$44M), up from 14% last quarter and 10% for all of FY2026. Q2 FY2027 is guided to $265–275M (+26% YoY at the midpoint), non-GAAP gross margin of 50.75–51.75%, non-GAAP opex of $84.5M ±$1M, and non-GAAP EPS of $0.23–0.26 — above consensus. The stock still fell about 5% to $40.08, roughly 42% below its June 30 close of $69.62.

Allegro beat and raised, and the stock fell anyway — it is now down about 42% from its June high after tripling in the first half of the year. The quarter was genuinely good, but three things get missed. First, the 27% growth headline is concentrated: Industrial and Other delivered $34.8M of the $55.8M year-over-year revenue increase — 62% of all the growth from 36% of the company — while Automotive, 64% of revenue, grew only 0.9% sequentially. Data center hit a record 17% of sales, up from 10% for all of FY2026. Second, the 'record profitability' story is measured off a bombed-out base: in FY2024 Allegro earned $1.049B of revenue at a 54.8% GAAP gross margin with $196M of operating profit and $0.78 of GAAP EPS. FY2027 will do more revenue at 48.5% gross margin and roughly half the GAAP earnings — a ~600bp hole management's own 50.75–51.75% non-GAAP guide concedes. Third, the operating leverage is real (a 50% incremental operating margin, opex +6.5% on revenue +27%) but partly funded by SG&A falling 5.4% while R&D rose 18.6%. Our owner-earnings DCF at a 9% discount rate lands at $27 base / $46 bull; we call fair value $28 against $40.08. The reverse DCF says the price requires ~22–23% free-cash-flow growth every year for a decade. Our call: AVOID, 2/5 — the crash was justified and isn't finished. Wall Street is Buy at a $54.43 average target, so we're CAUTIOUS and we differ.

THE CALL: AVOID (2/5, THE GROWTH IS REAL — THE PRICE ISN'T; A 42% CRASH THAT ISN'T FINISHED) — base-case value ~$28.00 vs ~$40.08 today.

What to watch: evidence the data-center mix is ACCRETIVE rather than dilutive — GAAP gross margin pushing back toward the mid-50s while data center keeps growing, plus Automotive resuming real sequential growth; get gross margin to 54% again on this revenue base and fair value moves toward the $46 bull case. The risk is the opposite: Automotive staying flat while data-center orders prove lumpy and hyperscaler-concentrated, because 62% of the year-over-year growth came from 36% of the revenue — one paused AI build could take the whole growth rate to zero. Watch the Automotive sequential line and the gross margin every quarter.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Verisk Analytics (VRSK) Q2 2026 — Verisk Analytics (VRSK) — the data monopoly behind the forms, rules and loss costs US property & casualty insurers write policies from — reported Q2 2026 (quarter ended June 30) before the open on July 29. Revenue was $806.3M (+4.3%, +5.8% organic constant currency), a slight beat; adjusted EPS $1.98 beat the $1.93 expected; FY26 guidance was reaffirmed. But GAAP net income FELL 9.8% to $228.6M — and the number nobody reported is that adjusted net income was $259.3M vs $264.4M, DOWN 1.9%. The 5.3% adjusted-EPS growth is entirely a 6.8% smaller share count. Our owner-earnings DCF lands at ~$180 vs the $213.15 July 29 close. Our call: HOLD, 3/5.

Verisk owns one of the widest moats in the market — its ISO forms, rules and loss costs are filed with state regulators and wired into nearly every US property & casualty carrier's workflow, which is why ~84% of revenue is prepaid, auto-renewing subscriptions. Q2 2026 looked like a clean beat until you read the reconciliation: adjusted net income fell 1.9%, GAAP EBITDA fell 2.0%, and GAAP EBITDA margin dropped 350 basis points to 54.2% — masked by adding back $18.7M of fees from the collapsed $2.35B AccuLynx acquisition, which the FTC ran out the clock on and which went to trial in Delaware Chancery June 23-26 with damages Verisk says are not estimable. Growth is price: the 10-Q says Underwriting grew 'primarily due to an annual increase in prices,' and with subscriptions +8.0% against 5.8% total organic growth, the ~16% transactional book is shrinking. The buyback was funded with leverage — cash fell from $2,178M to $551M, net debt rose $1.36B to $3.92B, interest expense is up 48.7%, and shareholders' equity is now a DEFICIT of $1.19B. Credit where due: stock comp is under 2% of revenue and is NOT added back to adjusted EBITDA. Our owner-earnings DCF (~$1,164M owner earnings, 9.0% discount rate, 6.5% growth fading to 4.5%, 2.5% terminal) lands at ~$180 versus the $213.15 close; the reverse DCF says today's price requires ~8% growth a year for a decade.

THE CALL: HOLD (3/5, A GREAT BUSINESS AT A PRICE THAT ALREADY ASSUMES THE RE-ACCELERATION — WATCH ADJUSTED NET INCOME, NOT ADJUSTED EPS) — base-case value ~$180.00 vs ~$213.15 today.

What to watch: transactional revenue stops shrinking, second-half organic growth prints inside the company's own 6-8% range, and adjusted NET INCOME — not just adjusted EPS — starts growing again. The risks: an adverse Delaware Chancery ruling in the AccuLynx case with damages Verisk says cannot be estimated, another year of price-only growth on a consolidating P&C customer base, or net leverage pushing past 2.5x to fund more buybacks

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Aurora Innovation, Inc. (AUR) Q2 2026 — Revenue was $2M (vs $1M a year ago, beating the $1.7M estimate) against a $266M operating loss and a $270M net loss — EPS of −$0.14 vs the −$0.117 consensus. R&D was $211M (+11%), SG&A $50M (+39%), and cost of revenue was $7M against $2M of revenue, so gross margin was about −250%. Aurora used ~$225M of operating cash plus $31M of capex, ended with ~$1.22B of cash and short-term investments, and sold 30M shares through its ATM for $215M net — money that, by the company's own description, funded $63M of employee cash bonuses and RSU tax withholding. Cumulative driverless miles since launch: about 440,000.

Aurora is the real thing technologically — driverless Class 8 trucks hauling commercially in Texas, zero Aurora-Driver-attributed collisions, an independently audited safety case, and Volvo, PACCAR and AUMOVIO lined up behind it. This episode is not about whether autonomous trucking happens. It is about what $5.95 a share already assumes. The one pricing tell in the quarter: management expects to exit 2026 with 200+ driverless trucks worth an ~$80M revenue run-rate — $400,000 per truck per year, which implies ~190,000 miles per truck, roughly double what a human-driven truck runs. Against a $1.04B annual GAAP operating cost and an estimated 35% mature gross margin, Aurora needs roughly 5,700–7,500 trucks to reach operating breakeven. The asset-light DaaS model starting in 2027 fixes the balance sheet but cuts revenue per truck to ~$80,000, so it needs closer to 16,000. Runway is about five to six quarters, so another $1.5–2.0B of equity gets sold first. Our reverse DCF says $5.95 already prices in ~18,000 driverless trucks in 2032; the Street's $12 needs ~35,000.

THE CALL: AVOID (4/5, GREAT TECHNOLOGY, PRICED FOR A FLEET THAT DOESN'T EXIST) — base-case value ~$3.75 vs ~$5.95 today.

What to watch: gross margin turning positive while the fleet is still growing — the proof the trucks pay for themselves rather than being subsidised by the equity. We would also raise our number on a disclosed per-mile commercial rate, on PACCAR attaching an actual date to series production, or on the year-end fleet landing above 200. Buyers under about $3.75.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.